What is Melanotan I?

Melanotan I is a synthetic peptide from the melanocortin group, representing a linear tridecapeptide and an analogue of α-MSH (α-Melanocyte-Stimulating Hormone). In scientific literature, it has been primarily investigated for its potential role in stimulating melanogenesis, photoprotection, and modulating skin pigmentation. The peptide acts primarily by activating the melanocortin receptor MC1R, with more limited activity toward other melanocortin receptors.

Originally developed as a research analogue of endogenous α-MSH, Melanotan I has been used to study pathways related to skin pigmentation, photoprotective mechanisms, and the response to UV radiation. Subsequently, interest in the peptide has included research into its effects on oxidative stress, inflammatory processes in the skin, and overall phototolerance.

Observations for Melanotan I

In scientific research, Melanotan I has been studied in connection with:

• Stimulation of melanogenesis – activation of MC1R in melanocytes and increased eumelanin synthesis

• Photoprotection – potential protective effect against UV-induced skin damage

• Improvement of phototolerance in models with increased sensitivity to sunlight

• Investigation of effects on oxidative stress and inflammatory mediators in the skin

• Modulation of skin tone and pigmentation uniformity

Administration and Dosage

In scientific literature, cited research dosage regimens vary depending on the model (in vitro, animal, or human studies) and the purpose of the study. With subcutaneous administration in a research setting, doses are usually titrated gradually to assess the dynamics of pigmentation and tolerability.

For 10 mg + 3 ml bacteriostatic water:

Concentration = 3.3 mg/ml → 0.075 ml ≈ 250 μg

Example calculated values for laboratory purposes:

0.075 ml ≈ 250 μg

0.15 ml ≈ 500 μg

0.3 ml ≈ 1000 μg

Specific administration schemes in scientific settings are determined according to the protocol design, the type of model, and the research objectives.

Scientific Data

Melanotan I has been studied in preclinical and limited clinical trials, with a specific focus on pigmentation and photoprotective effects.

• Primarily activates MC1R, leading to increased eumelanin synthesis and a darker phototype in the models studied

• In animal models, reduced damage from UV radiation and faster skin recovery after exposure are described

• In limited human studies, skin darkening and increased phototolerance have been reported

• Its action is not associated with a significant increase in GH or IGF-1 – the effects are independent of growth hormone

• Stable pigmentation levels have been observed for a certain period after cessation of administration in research settings

Possible Side Effects

In scientific literature, Melanotan I is generally well tolerated, but transient, dose-dependent reactions may occur:

• Facial flushing or a sensation of warmth

• Mild nausea or temporary stomach discomfort

• Headache or feeling of fatigue in some models

• Increased skin pigmentation and darkening of existing moles

The effects are usually reversible and resolve after cessation of administration in research settings. Serious adverse reactions are rarely described within the published doses, but long-term safety and effects on skin lesions remain subject to further study.

This information is based on scientific publications and is purely educational in nature. It is not intended for the diagnosis, treatment, or prevention of diseases and does not constitute medical advice.